Name | 5,5-diphenylhydantoin sodium sigmaultra |
Synonyms | solantyl solantoin dilantinsodium Phenytoin Sodium 5,5-DIPHENYLHYDANTOIN SODIUM 5,5-Diphenylhydatoin sodium salt 5,5-DIPHENYLHYDANTOIN SODIUM SALT 4-Ethyloctanoic acid methyl ester 5,5-diphenyl-hydantoimonosodiumsalt 5,5-diphenylhydantoinsodiumsigmaultra 5,5-diphenylhydantoin sodium sigmaultra 4-imidazolidinedione,5,5-diphenyl-monosodiumsalt |
CAS | 630-93-3 |
EINECS | 211-148-2 |
InChI | InChI=1/C15H12N2O2.Na/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12;/h1-10H,(H2,16,17,18,19) |
InChIKey | FJPYVLNWWICYDW-UHFFFAOYSA-M |
Molecular Formula | C15H13N2NaO2 |
Molar Mass | 276.27 |
Melting Point | 290-299°C |
Boling Point | 428.2 °C at 760 mmHg |
Solubility | Easily soluble in water, soluble in ethanol, almost insoluble in ether and chloroform. |
Appearance | White powder |
Color | White to almost white |
Merck | 14,7322 |
Storage Condition | Inert atmosphere,Room Temperature |
Sensitive | Easily absorbing moisture |
MDL | MFCD00069674 |
Physical and Chemical Properties | White powder, odorless. Melting Point 290-299 °c. Placed in the air can absorb moisture and carbon dioxide, the precipitation of phenytoin. Soluble in ethanol, water, insoluble in chloroform and ether. |
Use | Commonly used antiepileptic, treatment of trigeminal neuralgia and sciatica, antiarrhythmic and lowering blood pressure. |
Hazard Symbols | Xn - Harmful |
Risk Codes | R22 - Harmful if swallowed R43 - May cause sensitization by skin contact R62 - Possible risk of impaired fertility R63 - Possible risk of harm to the unborn child |
Safety Description | S22 - Do not breathe dust. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
UN IDs | UN 2811 6.1/PG 3 |
WGK Germany | 3 |
RTECS | MU1400000 |
HS Code | 29332100 |
Hazard Class | 6.1(b) |
Packing Group | III |
Toxicity | LD50 orally in mice: 490 mg/kg (Fink, Swinyard) |
Reference Show more | 1. Lu Haimei, Xie Meijuan, Li Shan, et al. Improvement of 6Hz corneal kindling drug-resistant epilepsy mouse model and effects of three traditional Chinese medicines [J]. Chinese Journal of Pharmacy, 2018, 053(007):1048-1053. 2. [IF = 2.196] Yang Lv et al."Central inhibition the in vivo acute toxicity of harmine in mice." Journal Of Biological Sciences. 2021 Jun 01 |
This product is 5, 5-diphenylhydantoin sodium salt. The content of C15H11N2NaO2 shall be between 98.0% and 102.0% based on the dry product.
take 0.5g of this product, add 20ml of water to dissolve, add 2ml of 0.4% sodium hydroxide solution, the solution should be clear and colorless.
Related substances
take this product, add the mobile phase to dissolve and dilute to make a solution containing about 1 mg per 1 ml, as a test solution; Take an appropriate amount of precision, A solution containing 10ug per 1 ml was prepared as a control solution by quantitative dilution with mobile phase. According to the chromatographic conditions under the content determination item, 20ul of each of the control solution and the test solution are accurately measured and injected into the human liquid chromatograph respectively, and the chromatogram is recorded to 3 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the sum of each impurity peak area shall not be greater than the main peak area of the control solution (1.0%).
take this product, dry to constant weight at 105°C, weight loss should not exceed 2.0% (for injection) or 2.5% (for oral use) (General 0831).
take 2.og of this product, add 37ml of water, boil and dissolve, let it cool, add 2.5ml of dilute hydrochloric acid, shake and filter; Take 20ml of filtrate, add 1 drop of phenolphthalein indicator solution and an appropriate amount of ammonia test solution to make the solution light red, add 2ml of acetate buffer solution (pH 3.5) and an appropriate amount of water to make 25ml, and check according to law (General rule 0821 method 1), heavy metals should not be more than 10 parts per million.
take this product, add 20ml of sterile water to dissolve, check according to law (General rule 1101), should comply with the provisions. (For aseptic dispensing)
measured by high performance liquid chromatography (General 0512).
silica gel bonded with octa-alkyl silane was used as the filler, and 0.05mol/L ammonium dihydrogen phosphate solution (adjusted to pH 2.5 with phosphoric acid)-acetonitrile-methanol (45:35:20) was used as the mobile phase; the flow rate was 1.5ml per minute; The detection wavelength was 220nm. Take appropriate amount of 2-hydroxy-1, 2-diphenylethanone (impurity I) and phenytoin sodium control, add a small amount of methanol to dissolve, diluted with mobile phase to produce impurities of approximately 10.15mg with phenytoin in 1 ml. The mixed solution of lmg is injected into the liquid chromatograph, and the peak sequence is phenytoin sodium and impurity I. The separation degree between the two peaks shall meet the requirements, and the number of theoretical plates shall not be less than 5000 based on the phenytoin sodium peak.
take this product, precision weighing, adding mobile phase to dissolve and dilute to make a solution containing about 50ug per lml, take 20ul for precision measurement, inject into liquid chromatography, record chromatogram; Take phenytoin sodium reference substance, same method determination. According to the external standard method to calculate the peak area, that is.
antiepileptic drugs, antiarrhythmic drugs.
sealed (for oral use) or sealed (for injection), protected from light.
This product contains phenytoin sodium (C15H11N2NaO2) should be labeled the amount of 93.0% to 107.0%.
This product is white tablet or film-coated tablet.
Take 20 tablets of this product, precision weighing, fine grinding, precision weighing appropriate amount (equivalent to phenytoin sodium 25mg), put it in 50ml measuring flask, add appropriate amount of mobile phase, shake for 30 minutes to dissolve phenytoin sodium, dilute to scale with mobile phase, shake well, filter, Take 5ml of filtrate accurately, put it in 50ml measuring flask, dilute to scale with mobile phase, shake well, as a test solution, 20 u1 was accurately measured, and human liquid chromatograph was injected to record the chromatogram. An appropriate amount of phenytoin sodium reference was additionally taken, the mobile phase was added and dissolved and diluted to prepare a solution containing about 50ug per 1 ml, which was determined by the same method. According to the external standard method to calculate the peak area, that is.
Same as phenytoin sodium.
(l)50mg (2 ) lOOmg
light shielding, sealed storage.
This product is a sterile powder of phenytoin sodium 10 parts mixed with anhydrous sodium carbonate 4 parts. Based on the average loading, the content of phenytoin sodium C15H11N2NaO2 shall be 93.0% to 107.0% of the labeled amount.
This product is white powder.
take the contents under the difference of loading amount, mix evenly, accurately weigh appropriate amount (about 25mg equivalent to phenytoin sodium), put it in a 50ml measuring flask, and add appropriate amount of mobile phase, shake to dissolve phenytoin sodium, dilute to the scale with mobile phase, shake well, take 5ml accurately, put it in a 50ml measuring flask, dilute to the scale with mobile phase, shake well, and use it as a test solution, 20 u1 was accurately measured, and the liquid chromatograph was injected to record the chromatogram. An appropriate amount of phenytoin sodium reference substance was accurately weighed, dissolved and diluted with mobile phase to prepare a solution containing about 50ul per 1 ml, which was determined by the same method. According to the external standard method to calculate the peak area, that is.
Same as phenytoin sodium.
(1)0.lg (2)0.25g
light shielding, closed storage.